Does State Medicaid Cover AndroGel?

How Medicaid Formulary Decisions Work for AndroGel

Each state runs its own Medicaid drug program under federal guidelines established by the Medicaid Drug Rebate Program (MDRP). There is no unified national formulary. A state Pharmacy and Therapeutics (P&T) committee reviews clinical evidence, cost data, and manufacturer rebate agreements to assign drugs to formulary tiers or exclude them entirely.

AndroGel (testosterone gel 1.62%, manufactured by AbbVie) holds FDA approval for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. Because branded AndroGel costs roughly $510 per month at list price, states face significant budget pressure. Generic testosterone gel formulations, which became available after patent expiration, typically cost 40% to 60% less and are preferred on most state preferred drug lists (PDLs).

States that participate in multi-state purchasing pools, such as the National Medicaid Pooling Initiative, may negotiate deeper rebates on branded products. This means a state's willingness to cover branded AndroGel over a generic can shift from year to year depending on rebate negotiations. Your state Medicaid pharmacy portal or a call to the state Medicaid pharmacy help desk will confirm the current PDL status.

Prior Authorization Requirements for AndroGel Under Medicaid

The vast majority of state Medicaid programs require prior authorization (PA) before approving AndroGel. PA criteria exist because testosterone replacement therapy (TRT) carries cardiovascular and hematologic risks that warrant clinical gatekeeping. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older, demonstrated that testosterone gel improved sexual function, physical activity, and mood, but also raised questions about cardiovascular safety that regulators continue to weigh.

Standard PA criteria across most states include:

• Confirmed diagnosis of male hypogonadism. Two separate morning serum total testosterone levels below 300 ng/dL (some states use 250 ng/dL or defer to the Endocrine Society's 2018 Clinical Practice Guideline threshold).
• Documentation that symptoms are present. Fatigue, decreased libido, erectile dysfunction, loss of muscle mass, or depressed mood.
• Exclusion of contraindications. Active or suspected breast or prostate cancer, untreated severe obstructive sleep apnea, uncontrolled heart failure, hematocrit above 50%, and desire for fertility within 12 months.
• Prescriber specialty. Some states restrict initial prescriptions to endocrinologists or urologists, though most allow primary care physicians to prescribe with adequate documentation.

The prescribing clinician or their staff submits the PA request, typically via an online portal or fax. Decisions usually arrive within 7 to 21 business days. Expedited or "urgent" PA reviews, which federal Medicaid rules require states to offer, must be resolved within 24 to 72 hours when a delay could seriously jeopardize a patient's health.

Step Therapy: What You May Need to Try First

Step therapy (also called "fail-first") is a cost-control policy requiring patients to try less expensive treatments before the insurer approves a costlier one. For testosterone replacement, the typical step therapy sequence looks like this:

Step 1: Generic testosterone cypionate intramuscular injections (200 mg/mL), which cost Medicaid programs as little as $15 to $40 per month. The patient must use this for 60 to 90 days.

Step 2: If injections are medically inappropriate or the patient has documented clinical failure (inadequate symptom improvement, injection-site reactions, needle phobia with documented behavioral health support, or inability to self-inject due to physical disability), the clinician can request branded or generic testosterone gel.

Step 3: Branded AndroGel specifically. Many states will approve generic testosterone gel at Step 2 but require a separate justification for the brand-name product, such as documented adverse reactions to the generic formulation or a pharmacokinetic argument that the branded product's delivery mechanism provides more consistent absorption.

Not every state imposes all three steps. A handful of states place generic testosterone gel on the PDL without step therapy but still restrict branded AndroGel. Your prescriber's office should pull up your specific state's PDL before selecting which testosterone product to prescribe. This one lookup can save weeks of back-and-forth.

State-by-State Coverage Variation

Coverage patterns fall into roughly three groups based on publicly available PDL data from state Medicaid pharmacy programs:

States with relatively open TRT coverage: States like New York, California, and Illinois tend to list generic testosterone gel on their preferred drug lists. Branded AndroGel may still require PA, but generic gel is accessible with a standard hypogonadism diagnosis. New York's Medicaid fee-for-service PDL, for example, lists testosterone topical gels as a covered class with PA requirements.

States with strict step therapy: Texas, Florida, and Ohio are among states that enforce multi-step therapy protocols. In Texas, the Vendor Drug Program requires documented failure of injectable testosterone before approving any topical formulation. Florida's Medicaid PDL similarly positions injections as the first-line covered option.

States with Medicaid managed care carve-outs: In states like Pennsylvania and Tennessee, Medicaid pharmacy benefits are administered by managed care organizations (MCOs) rather than a single state formulary. Each MCO sets its own PDL. A patient in Pennsylvania enrolled in one MCO might face different step therapy requirements than a patient enrolled in another MCO within the same state. The CMS Medicaid Managed Care Final Rule requires MCOs to maintain adequate pharmacy access, but specific drug coverage decisions remain at the MCO level.

The Endocrine Society's guidelines note that "testosterone therapy is recommended for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, muscle mass and strength, and bone mineral density" (Bhasin et al., 2018). Medicaid programs generally align with this recommendation for approval criteria, even when they restrict the specific formulation.

How to Appeal a Medicaid Denial of AndroGel

A denial is not the final word. Federal law guarantees every Medicaid beneficiary the right to a fair hearing when a benefit is denied, reduced, or terminated. The appeal process follows a consistent structure across states, though timelines vary.

Step 1: Internal reconsideration. Most states allow (and some require) the prescriber to submit additional clinical documentation before escalating to a formal appeal. This might include lab results, chart notes showing symptom burden, or a letter of medical necessity explaining why AndroGel specifically (not just any testosterone product) is required.

Step 2: State fair hearing request. If internal reconsideration fails, you or your prescriber file a fair hearing request with the state Medicaid agency. Federal regulations require states to act on fair hearing requests within 90 days, though many resolve faster. During the appeal, you may be entitled to continue receiving the medication if it was previously authorized and the denial represents a reduction in coverage.

Step 3: External review or court action. Some states offer an external medical review step. In rare cases, patients pursue legal remedies through state courts.

According to a Kaiser Family Foundation analysis, Medicaid fair hearing overturn rates vary significantly by state and drug class. For specialty medications, providing peer-reviewed evidence that supports the specific formulation (not just the drug class) strengthens the appeal. Citing the TTrials data showing that testosterone gel specifically was the formulation studied, with demonstrated benefits in sexual function (mean change in PDQ-Q4 score: 0.58, P<0.001) and physical activity, can support a formulation-specific medical necessity argument.

Dr. Shalender Bhasin, the lead investigator of the Testosterone Trials program, has stated: "The benefits of testosterone treatment in older men with low testosterone were moderate and varied across the different trials" (Snyder et al., NEJM 2016). This measured language from the principal investigator is useful in appeal letters because it demonstrates clinical nuance rather than overclaiming.

Cardiovascular Safety Considerations and Medicaid Scrutiny

State Medicaid programs have tightened TRT coverage partly in response to the FDA's 2015 label change requiring all testosterone products to carry a warning about possible increased cardiovascular risk. The FDA noted that the benefit and safety of testosterone for age-related low testosterone had not been established.

The TRAVERSE trial (N=5,246), published in The New England Journal of Medicine in 2023, provided the first large-scale randomized data on cardiovascular outcomes with testosterone replacement. The trial found that testosterone replacement in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease was noninferior to placebo for major adverse cardiovascular events (hazard ratio 0.99; 95% CI, 0.81 to 1.21). This finding has not yet led to widespread formulary liberalization, but it removes a key safety objection that Medicaid P&T committees previously cited when restricting coverage.

Prescribers filing PA requests should reference TRAVERSE when a Medicaid program denies based on cardiovascular concerns. The data directly addresses the FDA's 2015 warning and represents the strongest randomized evidence available on the question.

Monitoring Requirements That Affect Ongoing Coverage

Medicaid reauthorization for AndroGel typically occurs every 6 to 12 months. To maintain coverage, the prescriber must document:

• Serum testosterone levels within the target range of 400 to 700 ng/dL on therapy. Levels measured 2 to 8 hours after gel application.
• Hematocrit below 54%. The Endocrine Society guidelines recommend checking hematocrit at baseline, 3 to 6 months, then annually. Polycythemia (hematocrit above 54%) requires dose reduction or discontinuation.
• PSA screening. Baseline and follow-up PSA per the Endocrine Society's recommendation. A confirmed PSA increase exceeding 1.4 ng/mL within 12 months warrants urologic evaluation and may trigger Medicaid coverage suspension.
• Symptom reassessment. Some states require documented symptom improvement using validated tools such as the Androgen Deficiency in Aging Males (ADAM) questionnaire or the quantitative Aging Males' Symptoms (AMS) scale.

Missing any of these documentation checkpoints during reauthorization gives the Medicaid program grounds to deny renewal. Clinicians should build lab monitoring into their standard TRT workflow so that reauthorization submissions are routine rather than scrambled.

Generic Testosterone Gel vs. Branded AndroGel on Medicaid

For most Medicaid patients, the practical question is not whether AndroGel is covered but whether generic testosterone gel achieves the same result at lower cost and fewer administrative barriers.

Generic testosterone gel 1% formulations (manufactured by Teva, Perrigo, and others) contain the same active ingredient and are rated AB-equivalent by the FDA, meaning they meet bioequivalence standards. Absorption profiles may vary slightly between manufacturers due to differences in gel base composition, but clinical outcomes in large observational datasets show no meaningful difference in serum testosterone normalization rates.

The cost differential is substantial. Generic testosterone gel costs Medicaid programs roughly $150 to $250 per month versus $510 for branded AndroGel. This price gap explains why most state PDLs prefer generics. Patients who respond well to generic gel and maintain stable testosterone levels have no clinical reason to switch to branded AndroGel, and attempting to do so will create unnecessary PA friction.

The exception: patients who experience contact dermatitis, inconsistent absorption, or confirmed subtherapeutic levels despite adherence on generic gel have a legitimate medical necessity argument for branded AndroGel's specific formulation (1.62% concentration, metered-dose pump delivery).

Manufacturer Savings Cards and Medicaid

AbbVie offers a savings card for AndroGel that can reduce out-of-pocket costs. Federal anti-kickback statutes, however, prohibit the use of manufacturer coupons or savings cards with federally funded insurance programs, including Medicaid. This rule applies in all 50 states.

Patients enrolled in Medicaid cannot legally use the AndroGel savings card. Pharmacies should reject the coupon at the point of sale if Medicaid is the primary payer. There are no state-level exceptions to this rule. Patients who need financial assistance beyond Medicaid coverage should ask about AbbVie's patient assistance program (PAP), which provides free medication to qualifying low-income patients and is structured to comply with federal program integrity rules.